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Osteoporosis has a strong genetic component, but the genes involved are poorly defined. We studied whether the
sclerosteosis/van Buchem disease gene (SOST) is an osteoporosis-risk gene by examining its association with bone-
mineral density (BMD). Mutations in SOST result in sclerosteosis, and alterations in the SOST gene expression
may be causal in the closely related van Buchem disease. We used a set of eight polymorphisms from the SOST
gene region to genotype 1,939 elderly men and women from a large population-based prospective-cohort study of
Dutch whites. A 3-bp insertion ( ) in the presumed SOST promoter region (SRP3) was associated withfp 0.38
decreased BMD in women at the femoral neck (FN) ( ) and lumbar spine (LS) ( ), with evidence ofPp .05 Pp .01
an allele-dose effect in the oldest age group ( ). Similarly, a G variant ( ) in the van Buchem deletionPp .006 fp 0.40
region (SRP9) was associated with increased BMD in men at the FN ( ) and LS ( ). In both cases,Pp .007 Pp .02
differences between extreme genotypes reached 0.2 SD. We observed no genotype effects on fracture risk, for the
234 osteoporotic fractures validated during 8.2 years of follow-up and for the 146 vertebral prevalent fractures
analyzed. We did not find association between any of several frequent haplotypes across the SOST gene region
and BMD. We did find evidence of additive effects of SRP3 with the COLIA1 Sp1 polymorphism but not with
haplotypes of 3′ polymorphisms in the vitamin-D receptor gene. The SOST-COLIA1 additive effect increased with
age and reached 0.5 SD difference in BMD at LS in the oldest age group ( ). The molecular mechanismPp .02
whereby these moderate SOST genotype effects are mediated remains to be elucidated, but it is likely to involve
differences in regulation of SOST gene expression.
Introduction
Osteoporosis is a common disorder characterized by de-
creased bone-mineral density (BMD), degenerative mi-
croarchitectural changes in bone tissue, and an increased
fracture risk. Certain aspects of the disorder show strong
genetic influences. For example, the heritability of BMD
has been estimated to be up to 80%, which suggests the
existence of “bone density” genes (Smith et al. 1973; Po-
cock et al. 1987; Cummings et al. 1995; Flicker et al.
1995). Variance between individuals in the activity of
these genes may be manifested in different ways—for ex-
ample, by differences in peak bone mass or rates of bone
loss with increasing age. Although fracture risk is also
strongly inherited, it does not correlate absolutely with
BMD, which suggests that bone density and bone archi-
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tecture and/or strength probably are influenced by both
shared and distinct genetic factors (Cummings et al. 1995;
Flicker et al. 1996). In addition to genetic traits, the ex-
pression of osteoporosis is influenced by environmental
factors, such as diet, exercise, and exposure to tobacco,
alcohol, and sunlight. This multifactorial and polygenetic
character makes osteoporosis a so-called complex disease.
A number of approaches have been taken to try to
understand the genetic basis of osteoporosis (Uitterlinden
et al. 2001; Ralston 2002). Although genome scans in
large collections of related individuals have identified a
number of potentially interesting chromosomal loci (De-
voto et al. 1998, 2001; Duncan et al. 1999; Koller et al.
2000), significant linkage to the same loci is rarely ob-
served in more than one study. Furthermore, such rela-
tively large chromosomal areas still have to be searched
for candidate genes, variants of which could explain the
original linkage found.
In contrast, the candidate-gene approach builds on
biological knowledge to implicate particular genes in
bone metabolism. Evidence that would implicate certain
genes can include specific expression and function in bone
cells, genetically manipulated animal models with a bone
phenotype, and human Mendelian disease that expresses
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a bone phenotype. The contribution of genetic variations
in candidate genes involved in bone metabolism (forma-
tion, remodeling, microarchitecture, etc.) and bone den-
sity or fracture risk has been investigated in population-
based association studies. So far, polymorphisms in
several candidate genes have been investigated, including
those encoding collagen type I a1 (Grant et al. 1996;
Uitterlinden et al. 1998), vitamin-D receptor (VDR)
(Morrison et al. 1994; Uitterlinden et al. 1996), and es-
trogen receptor (Kobayashi et al. 1996; Becherini et al.
2000; van Meurs et al. 2003). “Risk alleles” for some of
these genes have been observed in some populations, but
the polymorphisms are generally associated with modest
effects on the phenotypes of interest. Of these, the col-
lagen type I a1 Sp1 polymorphism has been found, in a
number of studies, to be consistently associated with dif-
ferences in bone density and fracture risk, as demon-
strated by two meta-analyses (Efstathiadou et al. 2001;
Mann et al. 2001).
The gene that encodes sclerostin, or SOST, is mutated
in the disorder sclerosteosis (SCL [MIM 269500]), which
is characterized by massive, progressive bone overgrowth
throughout life (Hansen 1967; Beighton 1988; Balemans
et al. 2001; Brunkow et al. 2001). Along with thicker-
than-normal trabeculae and cortices, the BMD in affected
individuals can be up to twice that of unaffected indi-
viduals (Epstein et al. 1979; Stein et al. 1983). In contrast
to conditions that result in osteopetrosis, SCL is most
likely a defect in osteoblast function, as evidenced by
elevated alkaline phosphatase, increased rates of bone
formation, and generally normal numbers and activity
of osteoclasts. No obvious endocrinological abnormal-
ities have been reported. van Buchem disease (VBD
[MIM 239100]) is a similar disorder, with generally less-
severe clinical outcomes (van Buchem et al. 1955, 1976;
Beighton et al. 1984). Although the exact molecular
mechanism for its manifestation is unknown, a 52-kb
deletion located 35 kb downstream of the SOST gene
was suggested to play some role, perhaps by affecting
expression of SOST and/or other tightly linked gene(s)
(Balemans et al. 2002b; Staehling-Hampton et al. 2002).
Sclerostin is a cystine knot–containing, secreted glyco-
protein most similar in sequence to the DAN (differential
screening-selected gene aberrative in neuroblastoma)
family of bone-morphogenetic-protein (BMP) antago-
nists (Brunkow et al. 2001) and more distantly related
to the BMP antagonists noggin and chordin. Members
of the DAN family—including DAN, Cerberus/CER1,
Gremlin/DRM/CKTSF1B1, PRDC, Caronte, and Dante
(Hsu et al. 1998; Pearce et al. 1999)—exert their effects
by negatively regulating the activity of specific BMPs in
a wide variety of processes, such as differentiation, mi-
togenesis, chemotaxis, and apoptosis. The SOST gene
is expressed most highly in cells involved in osteoge-
nesis—specifically differentiated osteoblasts and osteo-
cytes—and, like its related family members, has been
shown to act via specific BMPs (Winkler et al. 2003).
This evidence, together with the very specific effect
on bone mass seen in the autosomal recessive disorder
SCL, led us to ask whether the SOST gene plays a role
in the genetic control of bone mass and/or predisposi-
tion to bone fracture in elderly individuals. We report
on the relationship of eight polymorphisms across the
SOST gene region to bone density and to the occurrence
of osteoporotic fractures in 1,939 elderly individuals
from a population-based prospective-cohort study of dis-
eases in the elderly in the Netherlands—the Rotterdam
Study (Hofman et al. 1991). Furthermore, we studied
the interaction between polymorphisms in the gene that
encodes sclerostin and polymorphisms in two genes pre-
viously implicated by us and others to play a role in the
genetic control of bone density and fractures—that is,
VDR and the collagen type I a1 gene (COLIA1).
Subjects and Methods
Study Subjects
Subjects were participants of the Rotterdam Study, a
population-based cohort study of subjects aged 55
years who live in the Ommoord district of Rotterdam.
The study was designed to investigate the incidence and
determinants of chronic disabling diseases in the elderly.
The rationale and design have been described elsewhere
(Hofman et al. 1991). All 10,275 Rotterdam inhabitants
who were aged 55 years were invited for baseline ex-
amination, between August 1990 and June 1993. Of
those, 7,983 participated. Among the subjects living in-
dependently, the overall response rate was 77% for home
interview and 71% for examination at a research center,
where anthropometric characteristics and BMD were
measured and blood samples were taken. The Rotterdam
Study was approved by the medical ethics committee of
the Erasmus University Medical School, and written in-
formed consent was obtained from each subject.
For the present study, a subgroup of men and women
was analyzed (see also Uitterlinden et al. [1998]). Base-
line measurements of BMD were available for 5,931
subjects who were living independently. Of those, 1,453
were excluded because they were aged 180 years, used
a walking aid, had diabetes mellitus, or were taking drugs
known to affect bone metabolism (diuretics, estrogen,
thyroid hormone, or cytostatic drugs). Of the 4,478 re-
maining subjects, we studied a random sample of 1,939
subjects comprising 1,016 women and 923 men.
Clinical Examination and Measurements
Height and weight were measured at baseline exam-
ination, with the subject in a standing position and wear-
ing indoor clothing but not shoes. BMD (in g/cm2) was
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determined by dual-energy X-ray absorptiometry (DEXA)
(DPX-L densitometer [Lunar]) at the femoral neck (FN)
and lumbar spine (LS) (vertebrae L2, L3, and L4), as
described elsewhere (Burger et al. 1994). Dietary intake
of calcium (in mg/d) during the preceding year was as-
sessed by a food-frequency questionnaire and was ad-
justed for energy intake. Age at menopause and current
use of cigarettes were assessed by a questionnaire.
Assessment of Incident Nonvertebral Fracture
Follow-up started either January 1, 1991, or at the
time of inclusion in the study, if later. For this analysis,
follow-up ended either by January 1, 2000, or at the
participant’s death, whichever came first. The general
practitioners of the participants provided data on mor-
bidity, including nonvertebral fractures, and mortality.
For ∼80% of the study population, medical events were
reported through computerized registers of general-prac-
titioner diagnosis. For the remaining 20%, research phy-
sicians collected data from the general practitioners’medi-
cal records of the study participants. All collected data
on fractures were verified by review of discharge reports
and letters from medical specialists. Fracture events were
coded independently by two research physicians, in ac-
cordance with the International Classification of Dis-
eases, 10th revision. In case of discrepancy, consensus
was attained in a separate session. A medical expert in
the field reviewed all coded events for final classification.
Assessment of Vertebral Fracture
Both at baseline and at follow-up visits, between 1997
and 1999, thoracolumbar radiographs of the spine were
obtained. The follow-up radiographs were available for
the 1,184 individuals who survived an average of 7.4
years after the center visit for baseline assessment and
who were still able to come to our research center. All
follow-up radiographs were scored for the presence of
vertebral fracture by the McCloskey/Kanis method (Mc-
Closkey et al. 1993), as described elsewhere (Van der Klift
et al. 2002; Schuit et al. 2004). If a vertebral fracture
was detected, the baseline radiograph was evaluated as
well. If the vertebral fracture was already present at base-
line, it was considered a baseline-prevalent fracture. If
it was not present at baseline, the fracture was defined
to be an incident. For 600 women and 519 men, lateral
radiographs of the spine from the 4th thoracic to the
5th lumbar vertebra were measured at follow-up and were
examined for the presence of prevalent vertebral frac-
tures by morphometric analysis, as described above.
Identification of SOST-Region Polymorphisms (SRPs)
We used a number of different approaches to search
for polymorphisms in the SOST gene region (see Brun-
kow et al. [2001] and GenBank [accession number
AF326736] for complete description of the SOST gene
structure): (1) a 21.5-kb genomic fragment—including
both coding exons, the ∼2.8-kb intron, and ∼12 kb of
5′ and ∼4.5 kb of 3′ flanking regions—was sequenced to
completion from four sources (Afrikaner, Dutch white,
and Senegalese individuals and human BAC clone 202l9
from California Institute of Technology BAC B and C
libraries); (2) the two coding exons were sequenced to
completion in a set of 90 ethnically diverse individuals
from the National Institute of General Medical Sciences
(NIGMS) Human Diversity Panel (panels HD01–HD09);
(3) an additional 87.6-kb region 3′ of the gene was sam-
ple sequenced in the four sources of (1) above, by use
of PCR primer pairs distributed across the region; and
(4) a sequence from the SOST gene region found in Na-
tional Center for Biotechnology Information (NCBI) da-
tabases was examined in silico. The examined SOST-gene
flanking regions correspond to the DUSP-SOST and
SOST-MEOX1 intergenic intervals (GenBank accession
numbers AF326736 and AF397423). All polymorphisms
found by these approaches were also compared with those
reported in a study by Balemans et al. (2002b).
Determination of Genotypes
Genomic DNA was extracted from samples of pe-
ripheral venous blood in accordance with standard pro-
cedures. Polymorphism-containing regions in the SOST
gene locus were amplified from genomic DNA with PCR.
Each PCR was performed in a 10-ml reaction volume
that contained 5 ng of genomic DNA, 1.5 mM MgCl2,
0.2 mM deoxy-NTP, 2 pmol of each primer (see table
1), 0.2 units of Taq polymerase (Promega), and 10#
PCR buffer (Promega) that contained 20 mM Tris-HCl
(pH 8.0), 100 mM KCl, 0.1 mM EDTA, 1 mM DDT,
50% glycerol, 0.5% Nonidet-P40, and 0.5% Tween20.
The reactions were performed in a 384-well thermocy-
cler (MJ Research Tetrad), with different cycling proto-
cols for each amplicon (table 1). The genotypes were
detected with the single-base extension (SBE) procedure
by use of SBE primers of different lengths (table 1). The
SBE reactions were performed in accordance with details
provided by the manufacturer (ABI Prism SNaPshot
Multiplex Kit), with slight modifications. The genotypes
thus generated were analyzed with software programs
Gene Mapper 1.1 and Genotyper 3.7 (both from Applied
Biosystems) and were checked visually. To confirm the
accuracy of the genotyping, 150 randomly selected sam-
ples were genotyped for a second time with the same
method. No discrepancies were found.
Three anonymous polymorphic restriction-enzyme-rec-
ognition sites at the 3′ end of the gene encoding VDR—
that is, for BsmI, ApaI and TaqI—were assessed in re-
lation to each other by a direct molecular haplotyping
PCR procedure, as described elsewhere (Uitterlinden et
Table 1
Rotterdam Study SRPs and Primers for SBE Genotyping
Polymorphism ID,
Positiona, and Alleles
Frequencies
( )Np 1,939 HWE P PCR Primers (5′r3′)
PCR TM
b
(C) SBE Primer (5′r3′)
SRP1:
4102c (7859):
C .72
.18 F: CTTTCCACAGGCTCGTCT; R: CTCTCAACCGGAAATGTCT 55 (T)4GAAGGTAGCGCCACCTGCTGG .28
SRP2:
10356c (1605):
C .60
.02 F: AGGTGGGGCTATAAGCATCCATCC; R: GTCCTTTGCCACCTGCCTCAACTT 55 (T)10TTGTGAGAAGCTGGCCCTCCT .40
SRP3:
10565c (1396):
DEL .62
.17 F: AGGTGGGGCTATAAGCATCCATCC; R: GTCCTTTGCCACCTGCCTCAACTT 55 (T)16ATGATGGATGATGGAAAGGAGGA .38
SRP4:
11988c (27):
G
NAe … F: TGCCCCAGCCTGTCCTCATT; R: GGCCGCCCTCCGTTCTC 55 NAeA
SRP5:
17965c (6004):
C .95
.89 F: TAAGGTGGGATGGTCAACTGG; R: CAGGAGAATCACTTGAATCCG 60 (T)22TAGTGGTAGTTAAACTGACAAG .05
SRP6:
18292c (6331):
A .42
.15 F: TAAGGTGGGATGGTCAACTGG; R: CAGGAGAATCACTTGAATCCG 60 (T)28AAGTTGCAGTAAGCCGAGATG .58
SRP7:
42722d (46121):
T .65
.93 F: CCCTACCTTACTGTCCGCCTCTCA; R: GTGCTACCTCTCGGGAAAACATAA 55 (T)34TTTAGTATAAAAGCTGGCTCC .35
SRP8:
58874d (62273):
A .65
.42 F: GAGCAACCGGCGTATCC; R: GGGGTTTCTTTCTGGCTCTCA 53 (T)40TTTATAGTTCTTTCCTAGACG .35
SRP9:
75707d (79106):
A .60
.34 F: CCAGCAATGTTGAGGAAT; R: CGCAGGAAGGTGTGGAGA 53 (T)46CTGCTCAGCAAGCAGTTCCAG .40
a Numbers in parentheses indicate position relative to SOST initiation site. SOST translational start site corresponds to nt 48 of GenBank accession number AF326739.
b Number of cycles p 37.
c Position of polymorphism in GenBank accession number AF326736.
d Position of polymorphism in GenBank accession number AF397423.
e NA p not applicable.
1036 Am. J. Hum. Genet. 75:1032–1045, 2004
al. 1996). This allowed us to determine the phase of the
alleles at each of the RFLP loci. As a result, three fre-
quent haplotype alleles were discerned—encoded 1 (baT;
frequency in whites 48%), 2 (BAt; 40%), and 3 (bAT;
10%)—that combined to become six genotypes encoded
11, 12, 13, 22, 23, and 33. We excluded the less frequent
haplotypes (4 and 5) from the analysis. Women with ge-
notypes containing these two haplotypes represent 1.5%
of this population. Detailed information on haplotype
alleles and genotype frequencies in the Rotterdam Study
can be found elsewhere (Uitterlinden et al. 1996). The
Sp1 polymorphism of COLIA1 was detected by PCR
with a mismatched primer that introduces a diallelic re-
striction site, as described elsewhere (Uitterlinden et al.
1998). The test discriminates two alleles, G and T, at
position exon 2 348, which is the first base in the last
of four Sp1-binding sites located in the first intron of
COLIA1 on 17q21 (Mann et al. 2001).
Statistical Analysis
Linkage disequilibrium (LD) and haplotype analy-
sis.—The LD coefficient (D′) between each pair of SNPs
was calculated with the help of the software programs
PHASE (Stephens et al. 2001) and HaploXT. PHASE
was also used to reconstruct haplotypes over the SOST
gene region (SRP1–6) for each individual. Hardy Wein-
berg equilibrium (HWE) was calculated, in accordance
with standard procedures, by use of the x2 analysis.
Association analysis.—Subjects were grouped on the
basis of genotype. We grouped subjects by allele copy
number (0, 1, and 2, corresponding to noncarriers, het-
erozygous carriers, and homozygous carriers, respec-
tively) for each allele (or haplotype). We allowed for three
possible genetic models to explain differences between
groups—that is, an allele-dose effect, a dominant effect,
or a recessive effect. “Allele dose” was defined as the
number of copies of a certain allele in the genotype. In
case of a consistent trend reflected as an allele-dose
effect, we performed a linear regression analysis to
quantify the association. In case of a dominant or re-
cessive effect of the test allele, analysis of (co)variance
(ANCOVA) was performed to test for differences be-
tween two genotype groups. For dominant alleles, we
compared test-allele carriers versus noncarriers, whereas,
for recessive effects, subjects homozygous for the test
allele were compared with heterozygous carriers com-
bined with noncarriers.
To study interaction of genetic variants (i.e., SOST with
VDR and SOST with COLIA1), subjects were analyzed
in four groups on the basis of presence or absence of
risk alleles for each gene. For reasons of power, we com-
bined heterozygous and homozygous subjects for the risk
allele into carriers of at least one copy of the risk allele.
Odds ratios (ORs) with 95% CIs were calculated by
logistic-regression analyses to estimate the relative risk
of fractures by genotype for the risk allele; the reference
group comprised those with no copies of the risk allele.
We first calculated crude ORs and then adjusted for po-
tentially confounding factors (e.g., age, BMI, BMD, and
age at menopause). To estimate nonvertebral fracture risk
by genotype, we used Cox proportional hazard models,
thereby taking into account potential differences in fol-
low-up time. To estimate the risk of vertebral fractures,
ORs with 95% CIs were calculated using logistic-re-
gression models. We were not able to use Cox propor-
tional hazard models for vertebral fractures, since the
exact time of the events were not known. For reasons
of power, all vertebral-fracture analyses were done with
combined prevalent and incident vertebral fractures.
All statistical analyses were performed using SPSS ver-
sion 10.1.0. P values are two-sided, and wasP  .05
considered significant.
Results
SOST Genotype, Allele Frequencies, and HWE
We identified a number of informative polymorphisms
in the SOST gene/VBD region by a variety of methods
(see the “Subjects and Methods” section). We found only
a single coding-region polymorphism that affected the
amino acid sequence of sclerostin. This G11988A variant
(SRP4) results in a ValrIle change in the signal sequence.
Our analysis of the SOST intron and flanking regions
identified an additional 30 SRPs (fig. 1). We determined
allele frequencies for 15 of the SRPs in a set of 90 normal
DNA samples, which represent 10 individuals of African,
30 of Asian, and 50 of white descent. Nine SRPs were
chosen for further study (SRP1–9) on the basis of their
distribution across the SOST gene locus and their rep-
resentation of a wide range (2%–50%) of minor-allele
frequencies. SRP1 (C4102G), SRP2 (C10356T), and
SRP3 (10565insGGA) are located in the 5′ flanking
region; SRP4 (G11988A) is in the sclerostin signal
sequence; and SRP5 (C17965G), SRP6 (A18292G), SRP7
(T42722C), SRP8 (A58874G), and SRP9 (A75707G) are
located 3′ of the gene, the latter three falling within the
region that is deleted in subjects with VBD (fig. 1) (Staeh-
ling-Hampton et al. 2002). There were no differences
found in allele frequencies between men and women (re-
sults not shown).
Although present in the NIGMS samples at a fre-
quency of 1.7%, the minor allele of SRP4 (Val/Ile in
SOST signal sequence) was not detected in a subset of
the Rotterdam elderly white sample and so was excluded
from the association study. The genotype distributions
for the remaining eight SRPs in the Rotterdam Study
were found to be in HWE ( ), except for SRP2P 1 .05
( ) (table 1).Pp .02
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Figure 1 Structure of SOST gene region and overview of polymorphisms. The SRPs described in this study span ∼87.3 kb of genomic
sequence. The two SOST exons are indicated by solid boxes, and the 52-kb VBD deletion region is indicated by the heavy horizontal dashed
line. Nucleotide positions are relative to the SOST initiation codon (1) and GenBank sequences AF326736 and AF397423. Polymorphisms
identified in the course of this study are compared with those reported by Balemans et al. (2002a) and those present in the NCBI SNP database
and are indicated below the gene map as well as by their presence () or absence (). Lack of a plus sign () or minus sign () indicates that
the corresponding region was not included in the study. The four most common haplotypes across SRP1–3 and SRP5–6 identified in the
Rotterdam Study population are also shown, with their respective frequencies (where alleles).np 3,878
LD and Haplotype Analysis
To get more insight into the pattern of LD between
alleles at polymorphic loci, pairwise disequilibria mea-
sures (D′) were calculated (fig. 2). Strong (although not
complete) LD was observed between the SRPs surround-
ing the SOST gene (SRP1–3 and SRP5–6) and, to a lesser
extent, between SRP7, -8 and -9. Using the PHASE pro-
gram, we reconstructed haplotype alleles for each subject
on the basis of the SRPs surrounding the SOST gene
(SRP1–6). These are shown in figure 1, together with
their frequencies in the 1,939 subjects from the Rotter-
dam Study. Because of the strong LD, we observed 4
frequent (15% population frequency) haplotype alleles
and 13 less frequent haplotype alleles among the 32
possible haplotypes. The four frequent haplotypes ac-
counted for 91% of the chromosomes in our population.
No differences in frequencies were observed between
men and women.
Association between Genotype and BMD
We next analyzed the association of SOST gene poly-
morphisms with bone characteristics for the individual
polymorphisms and for the haplotype alleles. We found
a significant association of BMD with SRP3 in women
and with SRP9 in men but not with the other six poly-
morphisms. Tables 2 and 3 show baseline characteristics
by SRP3 genotypes for women and SRP9 genotypes for
men, respectively. For both SRP3 and SRP9, the three
genotype groups did not differ significantly in age, an-
thropometric characteristics, dietary calcium intake, or,
for women, age at menopause.
Table 2 shows FN and LS BMD measurements in post-
menopausal women, grouped by the three SRP3 geno-
types. At both sites, BMD was highest in the homozygous
DEL-DEL group and lowest in the homozygous GGA-
GGA group; heterozygotes had intermediate values,
which indicates an allele-dose effect. BMD in the DEL-
GGA group was 2% less than the DEL-DEL group at
both sites, whereas, in the GGA-GGA group, BMD was
4% less than that in the DEL-DEL group (table 2)
( for FN; for LS). The effects of thePp .01 Pp .004
SRP3 genotype on BMD at the Ward’s triangle and tro-
chanter sites were similar (data not shown). When the
BMD values were adjusted for possible confounders, the
differences decreased somewhat. In men, no association
of SRP3 with BMD was found. When we compared
SRP3-allele frequencies between groups composed of
women in the highest and lowest quintiles of BMD, we
found the GGA-insertion allele to be overrepresented in
the lowest BMD quintile (data not shown).
The three SRP9 genotype groups differed significantly
in FN BMD and LS BMD in men, but no association was
found in women. At both sites, BMD was highest in the
Figure 2 Pairwise LD D′ values of eight SRPs across the SOST gene region. The software program PHASE was used to calculate values
by use of true genomic distance (A) and by use of the SRPs at equal distance from each other (B).
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Table 2
Characteristics of 1,016 Postmenopausal Women, by SRP3 Genotype
CHARACTERISTIC
FINDINGS BY SRP3 GENOTYPE
P
DEL-DEL
( )np 380
DEL-GGA
( )np 503
GGA-GGA
( )np 133
Frequency (%) 37 50 13
Age (years) 677 677 687 .27a
Height (cm) 1627 1626 1626 .80a
Weight (kg) 68.710.0 68.610.5 67.49.7 .40a
Age at menopause (years) 48.75.1 48.74.9 48.34.7 .69a
Dietary calcium intake (mg/d) 1,110389 1,104340 1,081291 .74a
Current smoker (%) 23 22 23 .91a
BMD (g/cm2):
FN:
Unadjusted .81.13 .80.12 .78.12 .01b
Adjustedc .81.12 .80.11 .79.11 .05b
LS:
Unadjusted 1.03.17 1.01.17 .99.18 .004b
Adjustedc 1.03.16 1.01.16 .99.16 .01b
a P value calculated with an ANCOVA test.
b P value calculated with a linear-regression model.
c Values are adjusted for age, weight, and height.
GG group and lowest in the AA group (table 3). BMD
in the GA group was 1% less than that in the GG group
at both sites, whereas, in the AA group, BMD was 3%
less than that in the GG group at both sites ( forPp .02
FN; for LS). The effects of the SRP9 genotypePp .03
on BMD at the Ward’s triangle and trochanter sites were
similar (data not shown). When the BMD values were
adjusted for possible confounders, BMD measurements
did not change essentially for LS, but differences in-
creased somewhat for FN. When we compared SRP9
allele frequencies between groups composed of men in
the highest and lowest quintiles of BMD, we found the
A allele to be overrepresented in the lowest BMD quintile
(data not shown).
We repeated the analyses using reconstructed haplo-
types that contained SRP3 for each subject, estimated
by the PHASE program. These analyses showed the asso-
ciations we observed to be driven by the individual poly-
morphism (SRP3) rather than by a particular haplotype
(data not shown). We also tried the same analyses with
haplotypes of SRP7–9, but reconstruction of the haplo-
types in each individual could not be estimated reliably
by PHASE.
Association between LS-BMD and SRP3 in Females Is
Age Related
BMD declines with age, and genetic effects on BMD
could theoretically be mediated by differences in the age-
related rate of bone loss as well as by differences in peak
bone density. We therefore assessed the effect of age on
the relationship between the SRP3 and SRP9 genotypes
and BMD. The study subjects were stratified by age into
tertiles (aged 55–63, 64–71, and 72–80 years). Figure 3
illustrates that, for SRP3, the differences in LS BMD
became larger with increasing age in females only. There
were no differences in LS BMD between the different
genotypes in the youngest age group, whereas an inter-
mediate difference in BMD appeared in the middle age
group. In the oldest age group, the difference in BMD
between the DEL-GGA group and the DEL-DEL group
was 4% ( [ANCOVA]), and the difference inPp .05
BMD between the GGA-GGA group and DEL-DEL
group was 8% ( [ANCOVA]). We found sig-Pp .004
nificant evidence to suggest an allele-dose effect of the
SRP3 GGA-insertion allele with decreased LS BMD
( ). When we tested for interaction between ge-Pp .006
notype and age, the interaction term did not reach sig-
nificance ( ).Pp .13
No age-related association between BMD and SRP3
genotypes was found at the FN site. Similar analyses for
SRP9 genotype in men found no effect of age on the
BMD differences between the different genotype groups.
No Association between SRP3 and SRP9 Genotypes
and Fractures
In our study population, during an average follow-up
period of 8.2 years, we captured 234 incident osteo-
porotic fractures (164 in women; 70 in men) and 146
prevalent vertebral fractures (81 in women; 65 in men).
Table 4 shows the distribution of fractures according to
the SRP3 genotype in females or the SRP9 genotype in
males. No significant differences were found between the
genotype groups. In addition, the risk estimates, as cal-
culated by regression analysis, did not show significant
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Figure 3 LS BMD in women, stratified by tertiles of age and by
SRP3 genotype. The three possible SRP3 genotypes are indicated by
diamonds (DEL-DEL), squares (GGA-DEL), and triangles (GGA-GGA).
P values for linear regression were adjusted for age, height, and weight.
The breakdown of subjects aged 71–80 years was DEL-DEL, np
; GGA-DEL, ; and GGA-GGA, .118 np 176 np 51
Table 3
Characteristics of 923 Men, by SRP9 Genotype
CHARACTERISTIC
FINDINGS BY SRP9 GENOTYPE
P
GG
( )np 154
GA
( )np 452
AA
( )np 317
Frequency (%) 17 49 34
Age (years) 677 677 677 .84a
Height (cm) 1757 1747 1757 .10a
Weight (kg) 77.89.9 78.010.4 78.612.4 .65a
Dietary calcium intake (mg/d) 1,132467 1,140385 1,154420 .86a
Current smoker (%) 30 29 36 .13a
BMD (g/cm2):
FN:
Unadjusted .88.13 .87.14 .86.12 .02b
Adjustedc .89.12 .88.13 .86.12 .007b
LS:
Unadjusted 1.17.20 1.16.19 1.13.19 .03b
Adjustedc 1.17.19 1.16.19 1.13.18 .02b
a P value calculated with an ANCOVA test.
b P value calculated with a linear-regression model.
c Values are adjusted for age, weight, and height.
differences from unity, even when adjusted for possible
confounding factors such as age, height, and weight (data
not shown).
Since the BMD association was observed to be partly
dependent on age, we also assessed the effect of age on
the fracture-risk estimates. For reasons of power, we
stratified the subjects into two age groups (aged 55–67
and 68–80 years). The same analyses as described above
were performed, but no significant association was found
(data not shown).
Interactions between SOST and VDR or COLIA1
Genotypes
We then studied possible interaction between poly-
morphisms in the SOST gene and two genes previously
found to be associated with differences in BMD; that is,
the VDR gene (12q13) and the COLIA1 gene (17q21.3).
We first analyzed VDR genotypes on the basis of hap-
lotypes constructed of three polymorphisms at the 3′ end
of the VDR gene, as described elsewhere (Uitterlinden
et al. 1996), in relation to SRP3 and SRP9 genotypes,
but we could not find evidence to suggest interaction or
additive effects on BMD or on fracture risk (data not
shown).
At the COLIA1 gene, we analyzed the GrT Sp1 poly-
morphism for which we previously demonstrated an as-
sociation with BMD and fracture risk in subjects from
the Rotterdam Study (Uitterlinden et al. 1998). In the
present study, we defined four groups of women, on the
basis of their combined genotype, by presence or absence
of risk alleles for COLIA1 and SOST. The groups were
those having no risk alleles (reference group), those hav-
ing at least one copy of the COLIA1 risk allele but no
SRP3 risk allele (the “COLIA1” group), those having
at least one copy of the SRP3 risk allele (the “SRP3”
group), and those having at least one copy of either
risk allele (the “COLIA1SRP3” group). We observed
a strong additive effect for these two polymorphisms.
Whereas SRP3 and COLIA1 Sp1 by themselves were
associated with decreased LS BMD, the combined-risk–
genotype group showed an even greater effect. Because
both SRP3 and COLIA1 Sp1 showed modification by
age, we next analyzed the additive genotype effect on
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Figure 4 LS BMD in women, stratified by tertiles of age and
by combined genotype for SRP3 and COLIA1 Sp1 polymorphisms.
The four possible genotype groups are indicated by diamonds (ref-
erence p no risk allele), squares (COLIA1), triangles (SRP3), and
circles (COLIA1  SRP3). ANCOVA P values were adjusted for age,
height, and weight. The breakdown of subjects aged 71–80 years was
reference, ; COLIA1, ; SSRP3, ; and COLIA1np 76 np 41 np 147
 SRP3, .np 74
Table 4
Distribution of Fractures and ORs by Genotype in Women and Men
DELETION REGION
AND GENOTYPE
FINDINGS FOR
Incident Osteoporotic Fractures Prevalent Vertebral Fractures
Percentage with Fracture
(No. with Fracture/Total) ORa (95% CI)
Percentage with Fracture
(No. with Fracture/Total) ORa (95% CI)
SRP3 (in women):
DEL-DEL 15.8 (60/380) 1.0 15.6 (36/231) 1.0
DEL-GGA 15.9 (80/503) 1.0 (.7–2.0) 11.5 (33/287) .7 (.4–1.2)
GGA-GGA 18.0 (24/133) 1.2 (.5–3.0) 14.6 (12/82) .9 (.5–1.9)
SRP9 (in men):
GG 7.8 (12/154) 1.0 13.3 (11/83) 1.0
GA 7.5 (34/452) 1.0 (.4–2.2) 11.7 (31/264) .9 (.4–1.8)
AA 7.6 (24/317) 1.0 (.4–2.3) 12.4 (23/172) 1.0 (.5–2.2)
a Unadjusted for possible confounders.
LS BMD by tertiles of age for all women (fig. 4). Our
results show that the additive effect is absent in the
youngest tertile, is becoming apparent in the middle ter-
tile, but shows greatest effect (0.5 SD) and reaches sig-
nificance ( ) in the oldest age tertile. When wePp .02
repeated the analysis of additive effects on risk of frac-
ture, no genotype-dependent effect was observed, but
numbers were small in each of the genotype groups
across the age groups.
Discussion
We and others have previously reported that loss-of-
function mutations in the SOST gene region cause SCL
(Balemans et al. 2001; Brunkow et al. 2001) and most
likely VBD (Balemans et al. 2002b; Staehling-Hampton
et al. 2002). These are monogenetic bone disorders with
a severe bone phenotype that involve generalized hy-
perostosis. A number of recent experiments support the
claim that the SOST gene product, sclerostin, is a key
regulator of bone mass (Winkler et al. 2003; Van Be-
zooijen et al. 2004). On the basis of the observed activi-
ties of sclerostin in vitro and in vivo, we hypothesized
that polymorphisms that occur in the SOST gene region,
which have more subtle effects on regulation of expres-
sion and function of sclerostin, might influence differ-
ences in BMD in the general population. We therefore
searched the SOST gene for frequently occurring DNA-
sequence variations and evaluated whether SOST poly-
morphisms are associated with parameters of osteopo-
rosis—that is, differences in BMD and in fracture risk—
in a population of elderly whites.
Of 31 total variants discovered in the area surround-
ing the SOST gene, we chose eight common polymor-
phisms and one rare polymorphism for further study.
The rare variant (SRP4) was the only example of a
polymorphism affecting the amino acid sequence of scle-
rostin (G11988A/Val10Ile in the signal sequence). Al-
though potentially of interest, its frequency was too low
(!3% in whites) to allow association studies of sufficient
statistical power, even in a population of the size we
had available ( ). Of the polymorphisms wenp 1,939
identified, several were present in the NCBI database or
had been published elsewhere (Balemans et al. 2002a).
The SRPs we identified in the VBD-deletion region are
new. The set of nine polymorphisms described in the
present study were selected to explore ethnic diversity
(SRP1–9) and then to look for association with osteo-
porosis in whites, as well as to analyze ethnic diversity,
LD, and haplotype structure (SRP1–3 and SRP5–9).
For most polymorphisms, the frequencies in the dif-
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ferent ethnic groups were similar (in particular, between
whites and Asians) (data not shown). We observed strong
LD in the immediate surroundings of the SOST gene
itself but much less LD with the polymorphisms in the
VBD deletion region, which comprises sequences ∼35–
87 kb downstream of the gene body. The existence of
such LD blocks of limited size (10–30 kb) is in line with
observations of other areas of the human genome (Krug-
lyak 1999; Dunning et al. 2000; Abecasis et al. 2001;
Daly et al. 2001; Reich et al. 2001). The strong LD is
also indicated by the limited number of haplotypes across
the SOST gene that we could reconstruct for whites in
our Rotterdam Study sample by use of the PHASE pro-
gram. The number of individuals in the other ethnic
groups (in the NIGMS panel) is too low to allow for
accurate LD measurement and reconstruction of hap-
lotypes. It will, however, be of interest to see if the
haplotypes we identified in whites are different from
those in Asians and African Americans, a comparison
of which could have important consequences for per-
forming and interpreting association studies by use
of these polymorphisms and haplotypes in nonwhite
groups.
In our association study of elderly whites, we ana-
lyzed eight polymorphisms that were, with the excep-
tion of SRP2, all found to be in HWE. In view of the
number of HWE tests we performed, we consider this
finding to be due to chance.
We observed the GGA-insertion allele ( ) offp 0.38
the SRP3 polymorphism to be associated with decreased
BMD in women (but not in men) at the FN and at the
LS. The difference between extreme genotypes was 0.2
SD, with evidence of an allele-dose effect. For the SRP9
polymorphism, we found the A allele ( ) to befp 0.60
associated with decreased BMD in men (but not in
women) at the FN and at the LS. Also, the difference
between extreme genotypes was 0.2 SD, with evidence
of an allele-dose effect. These associations seem real,
given the size of the population, their consistency (ef-
fects at several sites of BMD measurement), and the
plausible genetic model of gene-dose effects observed.
Although the lack of association for a given polymor-
phism in both sexes would argue against this, such dif-
ference between sexes is not unusual. For example, the
COLIA1 Sp1 polymorphism has been found to be as-
sociated with BMD only in women and not in men
(Uitterlinden et al. 1998; Mann et al. 2001). Although
we acknowledge the potential difficulty with multiple
comparisons in this study, several of the significance
levels we observed are impressive enough to withstand
conservative adjustments such as the Bonferroni cor-
rection. Together with the arguments presented above,
we think the genotype-dependent differences we observe
are modest but real. This situation is similar to that seen
for effects of common polymorphisms on other complex
traits (in addition to BMD and osteoporosis) (Loh-
mueller et al. 2003). Replication of our findings in other
large populations, with a similar age distribution fol-
lowed by meta-analysis, will help in establishing con-
sistency and true effect size of these polymorphisms
(Ioannidis et al. 2001).
When we analyzed the haplotypes across the SOST
gene and the VBD deletion region, we observed that the
associations were driven by the individual polymor-
phisms SRP3 and SRP9 rather than by a combination
of allelic variants present on a haplotype allele. This
could imply that there are no other important regulatory
polymorphisms either in the sclerostin-promoter region
or in the VBD deletion region, apart from the SRP3 and
SRP9 polymorphisms, respectively.
So far, no functionality has been established for the
SRP3 or the SRP9 polymorphisms. SRP3 is located ∼1.4
kb upstream of the SOST transcriptional start site and
thus may be important for interaction of promoter se-
quences with the transcriptional machinery. The inser-
tion/deletion polymorphism falls within a short region
that is highly conserved between humans and mice (80%
identity over 315 bp), which suggests functional signifi-
cance. In the absence of experimental data defining criti-
cal promoter sequences, we searched the TRANSFAC
database (Wingender et al. 2000, 2001) for consensus
binding sites for relevant transcription factors. SRP3
itself does not appear to fall within a known consensus
site; however, it is closely flanked by one HOXA9- and
two CBFA2-binding sites. It is also interesting to note
that the conserved element falls within a region that
appears to have a repressive effect on the activity of the
proximal SOST promoter, although it is not clear from
the published report which SRP3 allele was studied (Sev-
etson et al. 2004). The inclusion or exclusion of three
base pairs in the chromosome could be envisaged to
affect the interaction of DNA-protein complexes up-
stream and downstream of the region. For example,
given the loss-of-function phenotype associated with
SCL, one could propose that the SRP3 GGA-insertion
allele enhances expression of SOST mRNA (through an
effect on either positive or negative regulatory factors)
and consequently the sclerostin protein, thus leading to
decreased BMD. Molecular analysis of the SOST pro-
moter region and complete characterization of impor-
tant regulatory elements is necessary to establish the
influence of these subtle polymorphic variants.
Interestingly, Balemans et al. (2002a) also analyzed the
SRP3 polymorphism (termed “SNP5,” which carries a
TCC-insertion allele) but did not find any association
with BMD in a population of 619 white Scottish peri-
menopausal women. We believe this can be explained
by the age dependency that we observed for the associa-
tion of SRP3 with BMD in women. In our group of
women aged 55–63 years, which is close in age range
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to those in the Balemans et al. study, we failed to see
an association with BMD. Only when we examined
women aged 63 years did the association become ap-
parent, and we observed the genotype effect to further
increase with age. The SRP3 genotype effect, therefore,
seems to be restricted to older age categories, probably
due to modification by age-related factors. Such factors
could encompass gene-gene interactions and gene-en-
vironment interactions, such as changes in diet, changes
in hormonal factors, changes in mechanical loading, etc.
In this respect, it is of interest to note that sclerostin is
specifically and highly expressed in the osteocyte (Wink-
ler et al. 2003; Van Bezooijen et al 2004), a bone cell
that has been implicated in the mechanosensitivity of
bone tissue. The evident decrease of mobility with age
could therefore play an important role in the age-related
increase in the genotype effect we observed. However,
this obviously needs further study.
The GrA SRP9 polymorphism is located in the 52-kb
VBD deletion region, an area that, when deleted, leads
to a phenotype very similar to, albeit less severe than,
that seen in SCL (Balemans et al. 2002b; Staehling-
Hampton et al. 2002). Since there is no evidence of any
functional genes within the region, it has been postulated
that the VBD-deletion region contains important regu-
latory sites for the expression of sclerostin (Staehling-
Hampton et al. 2002). This notion is supported by recent
studies in transgenic mice (G. Loots, personal commu-
nication), although the exact mechanism by which SOST
gene expression is regulated remains to be elucidated.
Within the deletion area, several regions conserved be-
tween humans and mice have been identified, but SRP9
is not in any of these (B.W.P., S.P., and M.E.B., unpub-
lished data). Therefore, the functional relevance of the
SRP9 polymorphism for expression of sclerostin and how
it might influence differences in BMD later in life needs
further study.
In view of the importance of sclerostin in regulation
of BMD and the previous observations of other gene
variants that affect BMD, we studied combined effects
of such gene variants. In particular, we analyzed scle-
rostin polymorphisms in relation to the COLIA1 Sp1
polymorphism and the 3′ BsmI, ApaI, and TaqI VDR
polymorphisms. Although we could not see a combined
effect of SOST with VDR polymorphisms, we did see
an additive effect of the SOST SRP3 and the COLIA1
Sp1 polymorphisms. In addition, we observed that the
combined genotype effect increases with age. As dis-
cussed above, SRP3 is likely to affect expression of scle-
rostin, whereas the COLIA1 Sp1 polymorphism has
been demonstrated to result in increased expression of
the COLIA1 protein, which results in a slight excess of
COLIA1 homotrimers (Mann et al. 2001). Such homo-
trimers have been associated with decreased bone qual-
ity, including decreased BMD (Mann et al. 2001). Al-
though the molecular mechanism of the additive effect
of SOST and COLIA1 has not been established, varia-
tions in sclerostin expression are likely to interact with
variations in COLIA1 expression. As a BMP antagonist,
sclerostin is a key regulator of bone formation, a process
that involves production of collagen and subsequent
mineralization. Therefore, the production of collagen (in-
cluding homotrimers) is likely to be under the influence
of sclerostin regulation.
It has been well established that a decreased BMD
results in increased fracture risk, and several studies have
indicated that a 1-SD decrease in FN BMD is associated
with 1.5–2.5-fold increase in fracture risk (Schuit et al.
2004). Although we observed genotype effects on BMD,
we did not observe any effect of SRP3 or SRP9 on fracture
risk. We hypothesize that this lack of association of the
SOST polymorphisms with fracture risk is explained by
the modest effect size of these polymorphisms (0.2-SD
difference between extreme genotypes) and the fact that
the recognizable effect of the SOST polymorphisms is
probably restricted to BMD differences. Fracture risk is
only partly explained by differences in BMD, which
means that other factors, such as bone quality and bone
geometry, are at least as important in determination of
fracture risk. We analyzed a relatively large population-
based study in which 234 incident osteoporotic fractures
occurred and 146 prevalent vertebral fractures were di-
agnosed. This means that the methods set forth in our
study have substantial power to detect an increase in
fracture risk, given the SRP3 allele frequency of 38%.
Yet, in view of the small effect size of SRP3 on BMD,
we will need an even larger sample size than the one we
had available ( ) to detect such effects on frac-np 1,939
ture risk.
In conclusion, two variants in the SOST gene region
were associated with BMD differences and were found
to be modified by sex (SRP3 and SRP9) and by age
(SRP3). The effect size we observed on BMD was too
small to be detected as genotype-dependent differences
in fracture risk in our population study of 1,939 sub-
jects. The mechanism that underlies the BMD differ-
ences remain to be established but is likely to involve
modulation of expression of sclerostin. Further studies
in additional populations of elderly men and postmeno-
pausal women will be helpful in establishing consistency
of our findings and in estimating the true effect size of
these regulatory sclerostin polymorphisms.
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